Barbara Herkert

Title: Barbara Herkert: Innovator in Pharmaceutical Chemistry

Introduction

Barbara Herkert is a distinguished inventor based in Flonheim, Germany. She has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of innovative therapeutic agents. With a total of six patents to her name, her work focuses on addressing critical health issues.

Latest Patents

Among her latest patents are two notable inventions. The first is titled "Spiro bicyclic inhibitors of menin-MLL interaction." This invention relates to pharmaceutical agents that are useful for therapy and/or prophylaxis in mammals. Specifically, it involves spiro bicyclic compounds and their use as inhibitors of the menin/MLL protein/protein interaction, which can be beneficial in treating diseases such as cancer, myelodysplastic syndrome (MDS), and diabetes. The second patent is "Azepane inhibitors of menin-MLL interaction." Similar to the first, this invention focuses on azepane compounds and their pharmaceutical compositions, aimed at inhibiting the same protein/protein interaction for therapeutic purposes.

Career Highlights

Barbara Herkert is currently employed at Janssen Pharmaceutica NV, where she continues to advance her research and development efforts. Her work has been instrumental in creating new pharmaceutical solutions that can improve patient outcomes.

Collaborations

Throughout her career, Barbara has collaborated with notable colleagues, including Vineet Pande and Daniel Jason Krosky. These partnerships have enhanced her research and contributed to the success of her innovative projects.

Conclusion

Barbara Herkert is a prominent figure in the pharmaceutical industry, recognized for her innovative patents and contributions to medical science. Her work continues to pave the way for new treatments that address significant health challenges.